) is a standardized set of patient-reported outcomes (PROs) that cover physical, mental, and social health. The aim of this study was to develop the NIH PROMIS gastrointestinal (GI) symptom measures.
INTRODUCTION
Patients typically seek health care because they experience symptoms. Th is is especially true in gastroenterology where most digestive disorders initially present with symptoms rather than biochemical abnormalities alone. To fully describe the illness experience of gastrointestinal (GI) patients, providers must elicit, measure, and interpret patient symptoms as part of their clinical evaluation ( 1, 2 ) .
Patient-generated reports, also known as patient-reported outcomes (PROs), capture the patients ' illness experience in a structured format and may help providers understand symptoms from the patients ' perspective ( 1 ) . PROs measure any aspect of health directly reported by the patient (e.g., physical, emotional, or social symptoms) and can help to direct care and improve clinical outcomes ( 3 -9 ) . When clinicians systematically collect patient-reported data in the right place at the right time, PRO measurement can eff ectively aid in detection and management of conditions ( 3, 4 ) , improve satisfaction with care ( 5 ) , and enhance the patient -provider relationship ( 5 -9 ) .
Th e National Institutes of Health (NIH) launched the Patient-Reported Outcomes Measurement Information System (PROMIS ® ) in 2004 with the goal of developing, evaluating, and disseminating a toolbox of publicly available item banks capable of measuring PROs across the breadth and depth of the human illness experience ( www.nihpromis.gov ) ( 10 ) . Moreover, PROMIS measures are designed for either traditional paper-and-pencil or electronic modes of data collection. Th e NIH PROMIS vision is to create highly effi cient and short questionnaires that are feasible to implement in busy clinical systems while preserving reliability and validity. PROMIS is a system that off ers the potential for establishing common-language benchmarks for symptoms across conditions and identifying clinical thresholds for action and meaningful improvement or decline.
In the fi eld of gastroenterology, patients, providers, investigators, and regulators are interested in using PROs to guide clinical decision making ( 1 ) , conduct clinical research ( 1 ) , and achieve drug approval ( 11 ) . Over the past two decades, investigators have developed over 100 disease-targeted PROs that measure a range of GI symptoms ( 12 ) . However, the fi eld remains in need of a standardized, rigorously developed, electronically administered set of PROs that span the breadth and depth of GI symptoms, and can be used across all GI disorders for clinical and research purposes.
Th is paper describes content and cross-sectional construct validation of the NIH PROMIS GI symptom scales using data from diverse GI patients and members of the general population (GP).
METHODS

Study overview and objectives
We sought to develop and evaluate a new set of PROMIS GI symptom scales that capture the breadth and depth of physical symptoms associated with the GI system. We designed the scales to be applicable to both the GP and patients with a defi ned GI illness. Th e scales were designed to be system targeted for GI overall rather than disease targeted ; there are already over 100 disease-targeted scales in GI ( 12 ) . To develop the PROMIS GI symptom scales, we followed published criteria for qualitative and quantitative development of NIH PROMIS measures with oversight from the NIH PROMIS Steering Committee ( 10, 13, 14 ) . Th e study involved three phases conducted over a 4-year period: (i) development of candidate items (phase 1), (ii) qualitative item review (phase 2), and (iii) quantitative psychometric testing (phase 3). We describe the methods for each phase in the sections, below.
Phase 1: item development
Systematic literature review . We performed a structured search to identify English-language PROs across all luminal diseases and other illnesses that directly aff ect the GI tract (e.g., systemic sclerosis -a " non-GI " condition that aff ects GI function). Next, we developed a search strategy that targeted studies of English-language PROs that measure GI symptoms and abstracted individual items from each PRO to develop a comprehensive item library. Th en, we developed " bins " to categorize items describing GI symptoms, and used this to assess a framework for GI symptom reporting, similar to one developed previously for irritable bowel syndrome (IBS) ( 15 ) and in line with the process supported by the NIH PROMIS network ( 14 ) . Aft er binning items into defi ned categories, we " winnowed " items that were similar, leaving only items that covered unique symptom attributes. We presented our results to an expert panel consisting of three gastroenterologists with PRO expertise that provided feedback and identifi ed additional PROs and candidate items (William Chey (University of Michigan), Douglas Drossman (University of North Carolina), and Jan Irvine (University of Toronto)). We previously reported the extended methods and results of this search that culminated in the " GI-PRO database " -a publicly available search engine to identify extant GI PROs ( http://www.researchcore.org/gipro/ ) ( 12 ) .
Focus groups . In order to gain insights from patients about their GI-related symptoms, we conducted 12 disease-specifi c focus groups. We conducted the groups at the University of California Los Angeles (UCLA) and the West Los Angeles Veteran Administration (WLAVA) campuses between 13 November 2010 and 12 February 2011. Subjects were eligible if they were diagnosed by a physician with gastroesophageal refl ux disease, infl ammatory bowel disease (IBD), IBS, or systemic sclerosis (SSc); these conditions span the breadth and depth of GI symptoms. We next recruited participants across gender, ethnicity, and education levels and identifi ed patients through recruitment from the GI clinics at UCLA, WLAVA, and Cedars-Sinai Medical Center. Additional participants were recruited through fl yers distributed around UCLA clinics and through online advertisements using Craigslist. Before the focus groups, we developed a guide with patient instructions, open-ended think-aloud exercises, and scripted probes. An experienced moderator led each group with assistance from a co-facilitator (refer to Supplementary Appendix A online for the moderator ' s guide).
Each focus group lasted ~ 90 min and consisted of 6 to 12 participants (average 8 per group). Th e interviews were audiotaped and transcribed for analysis. Th ere were three focus groups for each of the four GI disorders.
We asked patients to describe their illness experience in their own words and without prompting. Th rough group interaction, we identifi ed common and unique language used to describe GI symptoms and their attributes. We conducted multiple groups to ensure that interactions of a single group did not bias any one conclusion and to provide greater generalizability.
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Qualitative data collection and analysis methods
We analyzed the transcribed focus group text using ATLAS. ti soft ware (ATLAS.ti Scientifi c Soft ware Development, Berlin, Germany) -a qualitative analysis program that allows coding of patient language and classifi cation of vocabulary into major and minor concepts. Th e evaluation process included generation of key words, phrases, and quotes regarding GI symptoms. To be considered credible, concepts needed to be raised in an unsolicited manner by more than one participant in a single group and by participants in more than one group. We used ATLAS.ti to generate code count histograms within major and minor symptom concepts, and developed a symptom network among concepts to depict a framework describing the breadth and depth of GI symptoms.
Phase 2: qualitative item review
Developing draft PROMIS items . Aft er developing our initial PRO item library and expanding it with input from patient focus groups, we next developed draft items. As the extant items varied in terms of phrasing styles, recall periods, response options, and literacy demands, we streamlined the items into a uniform style to create a harmonized item set using published PROMIS standards ( 14 ) . We employed the following principles to create new items for the PROMIS GI symptom banks:
Does not exceed a sixth grade reading level based on the validated " simple measure of gobbledygook " (SMOG) calculator ( 16 ) . Minimizes ambiguity or cognitive diffi culty. Avoids multi-barreled questions. Are as concise and simply worded as possible, attempting to use common English words and avoiding slang. Employ a 7-day recall period (standard PROMIS recall period ( 14 ) ). Meets criteria for optimal translatability into non-English languages, as established by NIH PROMIS " translatability review " by the PROMIS linguist. Next we created response scales for each item. For bothersomeness and interference of GI symptoms, we employed a fi ve-point categorical response scale ranging from " not at all " to " very much, " a preferred response scale for PROMIS ( 14 ) . For frequency items we used the PROMIS fi ve-level frequency scale ( 14 ) . For bowel controllability we employed the PROMIS fi ve-level capability scale ranging from " without any diffi culty " to " unable to control " ( 14 ) . For other items we created unique response sets that optimally suited the concept of interest, as necessary.
Patient cognitive debriefi ng for content validity . Following item development, we prepared a scripted interview to elicit patient feedback on the draft items. Th e script was based on guidance from PROMIS to evaluate respondent perceptions about language, comprehensibility, ambiguity, and relevance of item (see Supplementary Appendix B for moderator ' s guide) ( 14 ) . Th e purpose of these interviews was to identify potentially problematic items and response scales, to help clarify and rewrite items that were not well understood, and to add additional items ( 14 ) . Aft er each draft item was completed, an interviewer posed scripted probes to elicit the patient ' s perceptions about the item and its response choices. We employed a standard set of probes developed and published by the PROMIS network ( 14 ) . For example, following completion of an item, we asked: " In your own words, what do you think this question is asking? "
We obtained feedback from at least 10 patients from each patient group. Based on feedback and discussion, we created an updated set of items that included variations of the original items and additional items. Consistent with PROMIS standards, we then subjected the revised questionnaire to fi ve additional patient interviews ( 14 ) .
On the basis of these additional interviews and revisions, we craft ed a fi nal iteration of the items for subsequent testing. Finally, we classifi ed each item on a matrix referring to the dimension of interest (e.g., intensity, frequency, diffi culty, interference, predictability, bothersomeness) arranged in accordance with our previously described conceptual framework of GI symptoms ( 1, 12 ) . Th is process yielded our full PROMIS item set for subsequent psychometric evaluation, discussed below.
Phase 3: quantitative psychometric testing
In phase 3 of development, we sought to evaluate the psychometric properties of the PROMIS GI symptom scale by: (i) assessing the dimensionality of the scales and evaluating fi t of item response theory (IRT) models in patients with diff erent GI disorders and in representative members of the US GP; and (ii) evaluating the associations of the scales with legacy PRO instruments for GI illness and with patient-reported symptom severity. We tested the PROMIS GI Symptom scales in a diverse sample of GI patients and in a nationwide sample of the US GP for purposes of norming.
Selection of patients . We recruited participants from outpatient clinical practices and patients seeking care at university, community, and VA institutions. We invited patients seeking care at these outpatient clinics for an active GI symptom, including abdominal pain, bloating, nausea, vomiting, diarrhea, incontinence, constipation, dysphagia, or acid refl ux. Our sample included patients with IBD seeking care at Cedars-Sinai Medical Center, a tertiary center in Los Angeles; patients with GI symptoms from SSc seeking care at rheumatology clinics at the University of Michigan; patients with functional GI disorders seeking care at a specialty clinic at 
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UCLA; and patients with diverse GI conditions seeking care at a general GI clinic at WLAVA. In addition, we partnered with the IFFGD (International Foundation for Functional Gastrointestinal Disorders) to survey a cohort of patients with diverse functional GI disorders enrolled in IFFGD mailing lists. Th e overall goal of this recruitment strategy was to enroll a widely diverse population of GI patients with active symptoms, ranging in demographics, disease type, and disease severity.
All patients were invited to complete the confi dential online survey instrument, administered by Survey Monkey soft ware ( www.surveymonkey.com ). Patients without Internet access could request paper surveys sent to their home, or completed in clinic, as needed. Patients were excluded from participation if they failed to provide informed consent or if they had cognitive impairment that would interfere with participation.
Selection of controls . In addition to GI patient recruitment, Cint ( www.cint.com ), a survey research fi rm, recruited a sample of individuals representative of the GP in terms of gender, ethnicity, race, and education level based on the 2010 census. Subjects were required to be 18 years of age and able to read English; there were no other exclusion criteria applied to the GP sample. Cint maintains panels with several million subjects across the United States. Cint maintained the PROMIS survey open until such time as the survey met all prespecifi ed census-defi ned demographic requirements. Th is was completed within 3 weeks of opening the survey.
Measurements . In addition to the GI PROMIS Symptom items and demographic questions, we administered a wide range of concurrent legacy instruments that capture the biopsychosocial range of GI distress ( 2 ), including: (i) Visceral Sensitivity Index ( 17, 18 ) ; (ii) PROMIS global health items ( 19 ) ; (iii) GI-specifi c global health item ( " In the past 7 days, how would you rate your gastrointestinal condition? (excellent, very good, good, fair, or poor)); (iv) Gastrointestinal Symptom Rating Scale ( 20 ) ; and (v) EuroQOL health utility index ( 21 ) . In addition to completing the common set of legacy instruments, patients completed relevant disease-targeted legacy instrument: IBS patients completed the IBS-QOL (Irritable Bowel Syndrome Quality of Life) ( 22, 23 ) , IBD patients completed the IBDQ (Infl ammatory Bowel Disease Questionnaire) ( 24, 25 ) , and SSc patients completed the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (GIT) 2.0 ( 26 ).
Psychometric analyses . Overview of analyses : We fi rst calculated descriptive statistics for demographic characteristics of the GP subjects and GI patients, including age, gender, race / ethnicity, education, marital status, and employment. We then followed PROMIS methodology to conduct quantitative psychometric analyses of the PROMIS items with the goal of developing symptom-specifi c scales based on IRT assumptions ( 13 ) . Once these scales were created, we tested the construct validity of the resulting PROMIS scales against legacy instruments. In this report we present the cross-sectional psychometric analyses. Future reports will present longitudinal analyses including responsiveness to change and estimation of minimum clinically important diff erences for each scale.
IRT analyses : We fi rst evaluated the extent to which items satisfi ed the IRT assumptions of monotonicity and unidimensionality. Monotonicity means that the probability of selecting a more favorable response option increases as the underlying health increases, and vice versa. Unidimensionality means the items in a scale measure a common underlying symptom domain. We evaluated dimensionality using confi rmatory factor analytic methods. We fi tted confi rmatory categorical factor analytic models using MPLUS (Muthen & Muthen, Los Angeles, CA) in order to estimate polychoric correlations to adjust for ordinal rating scale data . We focused on practical fi t indices such as the comparative fi t index, as well as factor loadings and average absolute residual correlations to evaluate local dependence. We calibrated scales using the graded response model. Reliability and information : We estimated internal consistency reliability and information at diff erent points along the underlying scale for each PROMIS GI scale.
Construct validity : One method of establishing the validity of a PRO is to measure its relationship with other established legacy instruments. Th us, we hypothesized a priori that the PROMIS scales would signifi cantly correlate with the fi ve legacy instruments previously listed in the " Measures " section. We measured Pearson ' s correlation coeffi cients between each PROMIS GI symptom scale and each of the legacy instruments.
Th is study was approved by the institutional review boards of the West Los Angeles VA (PCC no. 0020), University of California at Los Angeles (IRB no. 11-003065), Cedars-Sinai Medical Center (PRO00027093), and the University of Michigan (HUM00052942), and was funded by grant NIH / NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research grant (AR052177).
RESULTS
Systematic literature review
Th e search strategy identifi ed 15,697 titles, of which 183 met our fi nal inclusion criteria Th ere were 126 PRO instruments comprising over 2,300 GI symptom items, described in a previous publication ( 12 ) . Item binning identifi ed eight overarching symptom domains: (i) abdominal pain, (ii) gas / bloating, (iii) diarrhea, (iv) constipation, (v) bowel incontinence / soiling, (vi) heartburn / refl ux, (vii) swallowing, and (viii) nausea / vomiting. We used these categories to guide our subsequent focus groups and item development.
Focus groups and cognitive interviews
Participants . Table 1 shows demographic information of the 130 total participants in the qualitative research phase (102 in focus groups and 28 in cognitive interviews). Th e sample was demo-
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tion (i.e., feeling pressure or fullness), (ii) bloating appearance (i.e., belly swollen or larger than usual size), (iii) fl atulence (i.e., passing gas), and (iv) gurgling or rumbling. Th e fi rst two facets refl ect that bloating was described in terms of both its look and feel. " Flatulence " is a related but separate symptom that indicates passing gas (in contrast to gas retention with subsequent visible bloating). Flatulence was largely considered to be a discomfort symptom grouped within the bloating complex rather than as a defecation-related symptom, principally because fl atulence most oft en occurs outside the context of bowel movements. Th e fourth facet is another related but separate symptom that refers to abdominal sounds. Gurgling or rumbling sounds were associated with gas and bloating. Th e gas / bloat domain items assess: (i) the frequency, sensation, appearance, predictability, and impact (bothersomeness and / or impact on daily activities) of gas / bloating during the past 7 days; (ii) the frequency and impact of fl atulence during the same period; and (iii) the frequency of gurgling or rumbling during the same period.
Domain name: diarrhea : Diarrhea refers to loose, watery stools, urgency, and frequent bowel movements. Th e diarrhea items focus on capturing the frequency, form, bothersomeness, impact, controllability, and predictability of bowel urgency during the past 7 days. Domain name: constipation : Constipation is the second defecation domain and encompasses the facets or cardinal subsymptoms of incomplete evacuation, straining, infrequent stools, and hard stools. Associated symptoms of rectal pain and need for manual maneuvers to facilitate stool evacuation are also assessed. Th e constipation domain items address the frequency, intensity, bothersomeness, and / or impact of all these facets of constipation during the past 7 days. Domain name: bowel incontinence : Th is domain encompasses symptoms pertaining to a spectrum of bowel incontinence. Bowel incontinence was usually described as " having accidents " by most patients. Th is can be associated with bowel urgency or it can occur without the patient ' s awareness. In addition, however, some patients described stool leakage or " soiling " as a separate yet related symptom. Some patients described " passing gas " but subsequently fi nding out they also soiled their underwear, referred to as " gas incontinence. " Th e bowel incontinence domain terms address frequency of these symptoms during the past 7 days. Domain name: gastroesophageal refl ux (GER) : GER is the fi rst of three domains associated with the foregut. Th e GER domain items assess four facets of patients ' GER-related symptoms, including: (i) sensations associated (refl ux, regurgitation) or unassociated (lump in the throat) with food intake; (ii) painful sensations (heartburn, chest pain, throat burn); and (iii) belching gas (burping) / hiccups. Th e GER items address the frequency, amount, bothersomeness, and / or impact of these symptoms during the past 7 days. Domain name: nausea / vomiting : Th e nausea / vomiting domain encompasses a range of increasingly severe foregut symptoms graphically and clinically diverse. Of the 130 participants, there were 29 % , 25 % , 21 % , and 25 % with a functional GI disorder, IBD, SSc, and gastroesophageal refl ux disease, respectively.
ATLAS.ti coding results
. Participants in the focus groups spontaneously reported a diverse range of symptoms. Analysis of the transcripts yielded 42 unique codes grouped into the eight symptom domains. Figure 1 shows the resulting conceptual framework resulting from ATLAS.ti coding of the symptom described by patients.
Qualitative item and scale development . Based on the literature search and focus groups, we developed candidate items within eight symptom domains. Overall, we found that the items were widely considered to be simple, understandable, and relevant in cognitive interviews. Aft er iterative modifi cation of the items, we developed 102 items contained within eight hypothesized domains, defi ned below based on qualitative item development: Domain name: abdominal pain : Similar to previous work ( 15,27 ), we found that abdominal pain is multifaceted and can vary in location, intensity, and quality. Patients described how certain dimensions of pain drive illness severity more than others. Th e intensity, nature (sharp vs. dull), frequency, bothersomeness, and predictability (e.g., ability to tell in advance when a pain episode would occur) all contributed toward GI pain severity. In addition, patients indicated that involvement of more abdominal regions was related to higher pain severity. Th e items in the resulting PROMIS abdominal pain scale assess all dimensions of abdominal pain experienced over the past 7 days. Domain name: gas / bloating : Th e gas / bloating domain includes four facets: (i) bloating sensa- Wet gas (i.e., thing it will be gas, but get a surprise instead)
Food sticking in the chest 
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Refer to Supplementary Appendix C for the full set of PROMIS items. Th ese will also be available online at the NIH Assessment Center ( http://assessmentcenter.net/ ). In addition, we provide detailed scoring instructions and lookup tables in Supplementary Appendix D .
Psychometric evaluation
Patient characteristics and descriptive statistics . We recruited 865 patients to complete the online survey out of 2,217 invitations distributed among our partner clinics (39 % response rate). Cint enrolled 1,177 GP subjects before closing the survey because of meeting enrollment criteria. Table 2 presents the demographics characteristics of both samples. Th ere was no signifi cant diff erence in age or gender, but there were signifi cant diff erences in race / ethnicity, education, marital status, and employment status. Of the GI patients, the most common diseases were IBS, gastroesophageal refl ux disease, chronic constipation, IBD, and SSc. Notably, GI conditions were commonly reported in the US GP sample as well, demonstrating the high population prevalence of GI symptoms and related conditions.
IRT analyses . Table 3 provides a summary of fi t statistics for confi rmatory factor analysis of calibrated PROMIS GI symptom scales. All the calibrated items had high fi t indices supporting unidimensionality. Th e item properties from calibration are available in Supplementary Appendix E .
PROMIS GI symptom scale scoring . We calibrated each scale using the two-parameter IRT graded response model and scored on a T metric (the NIH PROMIS standard) with a mean of 50 and s.d. of 10 in the US GP. Table 4 presents the mean scores among the GI patient population. With the exception of gastroesophageal refl ux symptoms, the mean PROMIS scores were signifi cantly higher in the patient population vs. GP. Table 5 shows the correlations among the PROMIS GI Symptom Scales. Supplementary Appendix D demonstrates how to convert the scales into percentile scores, where each respondent is compared against the US GP on an easily interpreted percentile scale.
that include " feeling sick to the stomach, " decreased appetite, dry heaves, and fi nally vomiting up stomach contents. Th e nausea / vomiting domain items assess the frequency, severity, and / or predictability of these symptoms during the past 7 days.
Domain name: disrupted swallowing : Disrupted swallowing encompasses an array of symptoms described by patients ranging from pain to diffi culty swallowing solids and / or liquids to food getting stuck in throat or chest when eating. Th e disrupted swallowing items assess the frequency of these swallowing-related symptoms during the past 7 days. GERD, gastroesophageal refl ux disease; GI, gastrointestinal; GP, general population; HS grad, high school graduate; IBD, infl ammatory bowel disease; IBS, irritable bowel syndrome. * P < 0.05 comparing GP vs. patient groups. Note that patients could endorse more than one GI condition. The most common " other " GI conditions were: intestinal surgery ( N =72), symptomatic divertic-
, and gastroparesis ( N =11). Construct validity . Table 6 provides evidence of construct validity for all eight PROMIS GI symptom scales compared with legacy instruments. Overall, the correlations between PROMIS GI symptom scales and the wide range of legacy instruments were statistically signifi cant and in the anticipated direction.
DISCUSSION
Th e eight NIH PROMIS GI symptom scales capture the breadth and depth of GI symptoms experienced by people with a wide range of digestive disorders. Unlike disease-targeted measures, which are designed for specifi c patient populations, the PROMIS GI symptom scales are system-targeted measures designed for anyone experiencing a GI symptom -whether patients or members of the population at large. Th is is an important distinction of PROMIS measures, because disease-targeted PROs are not useful across the population as a whole. PROMIS aims to support rigorously developed PROs that are applicable to all comers. Similar to other PROMIS measures, the PROMIS GI scales are normed against GP distributions allowing for relative interpretation of symptom scores. As with clinical biomarkers, such as hemoglobin or creatinine levels, PROMIS scores are interpreted in relation to a background distribution of symptom experiences. For example, Figure 2 shows sample results from a patient who completed the NIH PROMIS GI symptom scales using a computer administered patient -provider portal before a GI offi ce visit ( 1 ) . Th e " heat map " reports which of the eight symptoms the patient experienced over the past week, and records the symptom severity among the positively endorsed symptoms. Although the PROMIS scores are reported on a T metric, they can be easily converted to a percentile score against the US GP, as illustrated in Figure 2 . We provide instructions in Supplementary Appendix D for how to calculate the PROMIS scores and convert them to percentile scores using lookup tables.
Th e PROMIS GI symptom scales are will become publicly available for download on the NIH PROMIS Assessment Center ( http:// assessmentcenter.net/ ). Th e Assessment Center provides score reports and T metric heat maps for users. Future functionality will yield age-and gender-normed scores. Even without Assessment Center, the instructions in Supplementary Appendix D allow for programming scores onto local systems as needed.
Th e PROMIS GI symptom scales can also be used for research. Th ese scales off er the common-language benchmarks for symptoms across varied conditions. Th is provides a standardized outcome for epidemiological and clinical intervention trials. Future Higher score denotes better health-related quality of life (HRQoL). c Higher score denotes more GI-associated visceral sensitivity. set of legacy instruments spanning from disease targeted (e.g., IBS-QOL, IBDQ, and SSc-GIT) to system targeted (e.g., Visceral Sensitivity Index and Gastrointestinal Symptom Rating Scale) to generic PROs (e.g., EuroQOL and PROMIS global health). Finally, unlike existing PROs in gastroenterology, the PROMIS GI symptom scales were also tested in the GP, thus off ering a scale that is applicable to anyone with GI symptoms, regardless of whether they are seeking care for their symptoms.
As with any PRO development eff ort, the PROMIS GI symptom scales have limitations. Although we identifi ed a wide range of patients representing the breadth and depth of typical GI symptoms, we did not include subjects from many GI conditions, such as GI malignancies or chronic liver diseases. Other common conditions, such as celiac sprue, had only small numbers of participants in this initial validation trial. Th e scales also do not measure signs like recreports will present the longitudinal construct validity of the PROMIS GI symptom scales and minimally important diff erence estimates -additional attributes to assist with prospective intervention trials in gastroenterology.
Th e PROMIS GI symptom scales off er methodological and administrative advantages. Following the PROMIS methodology and constructed with oversight by the NIH PROMIS Steering Committee, the scales have been rigorously developed using modern psychometric techniques. Th is started with a grounded conceptual framework based on a systematic literature review and extensive patient focus groups. Th e participants ranged widely by demographics, GI disorders, and illness severity. Th e items were craft ed to be understandable at a sixth grade level, and to be applicable to both patients and the GP at large. Support for the construct validity of the resulting scales was found using a diverse Figure 2 . Sample " heat map " patient report of gastrointestinal (GI) Patient-Reported Outcomes Measurement Information System (PROMIS) scores. Patient scores are compared with the general US population benchmarks to add interpretability to the scores, similar to a lab test. For this use case, a provider can immediately detect that the patient reported many GI symptoms, but that constipation was the most severe and bothersome, falling within the top quartile of severity compared with the general population (GP). Gas and bloating were also elevated in this patient, falling in the third quartile of severity. In contrast, although the patient reported abdominal pain and heartburn / refl ux symptoms, those scores were only in the fi rst and second quartiles compared with people in the GP with similar symptoms. For instructions on how to convert PROMIS scores to percentile, see Supplementary Appendix D . *Patients "most bothersome" symptoms.
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NIH PROMIS GI Symptom Scales tal bleeding or weight loss. Future research is needed to evaluate the PROMIS GI symptom scales in other conditions and populations. In addition, the scales are currently designed for adult populations; we hope that future work will focus on using the PROMIS methodology in pediatric GI populations. Th e scales are further limited by their 7-day recall period; they are not currently suitable for momentary assessments, or for use as a daily diary. Future research should test retrofi tted scales that can apply to shorter recall periods; this may be especially important for use of PROMIS in pharmaceutical trials. Finally, we did not validate the item bank against objective tests such as upper GI endoscopy, motility studies, or other diagnostics. Previous studies have shown that PROs complement the objective tests in clinical care and future research should assess the role of GI PROMIS in achieving this goal ( 28, 29 ) .
In conclusion, we developed the NIH PROMIS GI symptom scales -a publicly available set of valid and reliable PROs for use in people with GI symptoms. Th e eight scales can be used together or individually for clinical practice and clinical research in a diseaseagnostic manner. Th e scales are broadly applicable across populations, GI symptoms, GI diseases, and demographics. Future work will report the longitudinal validity of the scales, including how they track with patient reports and physician illness assessments, and will evaluate how use of the scale aff ects clinical outcomes in diverse GI populations.
